次世代エネルギー産業・グリーン経済の国際リサーチ情報サイト

医薬品販売業務受託(CSO業界)の世界市場2015-2025年

Pharma Contract Sales Industry and Market: Trends and Forecasts 2015-2025

出版元:Visiongain(英国)出版元情報LinkIcon
発行年:2015年3月
定価 Single User License(1名様ライセンス) 1,799 GBP(英国ポンド) / Department License(5名様ライセンス) 2,999GBP/ Site License 4,999GBP / Global Site License 6,999GBP
ご請求は円換算(お見積り日TTSレート)となります。
納品形態:PDF by Email (※デジタル著作権管理/DRM設定有り)
当調査レポートは英文216ページになります。
商品コード:VGN350

お問い合わせ、お見積りのリクエストは下のボタンをクリックしてご入力ください。


【レポート紹介】
医薬品販売業務受託(CSO)の世界市場はサービスへの需要増加の追い風を受けており、2019年段階で市場規模は64億6000万ドルへと拡大し、さらに2025年にかけて力強い成長が予測されます。
当レポートでは世界市場規模予測(2015-25)、ディテーリング、非人的プロモーションなどのサービスカテゴリ別、および癌治療、心疾患治療、メタボ治療等の治療分野別のセグメント市場予測、主要国別市場予測などの詳細データを掲載しています。またリーディング企業動向、市場動向分析、専門家オピニオンインタビューなどの分析情報も織り交ぜ、概略以下の構成でお届けいたします。


【レポート構成概要】
・医薬品販売業務受託(CSO)の世界市場予測2015-2025年

・セグメント別市場予測2015-25VGN350_Pharma Contract Sales Industry and Market Trends and Forecasts 2015-2025 Cover.jpg
フィールドセールス(ディテーリング)
非人的プロモーション(以下のサブセグメントデータあり)
- テレディテーリング
- e-ディテーリング
医薬品教育
サンプル管理サービス
その他委託販売サービス
(治療分野別)
- がん治療
- 心血管疾患治療
- メタボリック疾患治療Metabolic disorder

・主要11ヶ国、国別市場予測2015-25
- 米国
- 日本
- ドイツ、フランス、英国、イタリア、スペイン(国別)
- EU地域
- ブラジル、ロシア、インド、中国(BRIC諸国、国別)

・市場動向分析(諸論点)
- アウトソースとインハウス販売営業、トレンド、販売モデル、マルチチャネルマーケティング
- CSOの提供サービスと製薬企業のベネフィット
- 成熟ブランドと新製品ローンチ、フィールドセールスの柔軟性
- 当局規制の展望、新規参入要件
- オンラインマーケティングの変化とあらたなIT技術活用のポテンシャル
- リスク・シェアリング合意、キーアカウント管理(KAM)、キーオピニオンリーダー(KOLs)とメディカル・サイエンス・リエゾン(MSL)
- ディテーリングに活用されるスマートフォンとタブレット端末。通信技術の進化
- クローズド・ループ・マーケティング(CLM)、クラウドコンピューティング、顧客関係管理(CRM)、ソーシャルメディアとビッグデータ
- インハウス販売営業の人員配置基準の変化、アウトソースサービスへの需要増加
- 戦略的提携とCSO再編
- 生物製剤、バイオシミラー、希少疾病治療薬、その他特殊治療薬の販促

・リーディング企業プロフィール、動向分析
- Quintiles
- inVentiv Health
- UDG Healthcare
- Publicis Touchpoint Solutions
- OnCall
- PDI

・業界企業オピニオンインタビュー:
- Walter R. Dewees, Executive Vice-President, OnCall LLC
- Tony Swift, Managing Director, Apodi, UK
- Holger C.W. Fürstenberg, CEO, Hilver, the Netherlands

・調査結論
(全216ページ、77個のデータ表、64個のチャート)

Visiongain is a trading partner with the US Federal Government
【レポート詳細目次、データ項目一覧(List of Tables)は当ページ下を参照ください】

英文詳細目次(table of contents)

【原文詳細目次】

Pharma Contract Sales Industry and Market: Trends and Forecasts 2015-2025

Table of Contents

1. Report Overview

1.1 Pharma Contract Sales: World Market Review 2014
1.2 Why You Should Read This Report
1.3 How This Report Delivers
1.4 Main Questions Answered by this Analysis
1.5 Who Is This Study For?
1.6 Methods of Research and Analysis
1.7 Frequently Asked Questions (FAQs)
1.8 Some Associated Reports
1.9 About Visiongain

2. Defining the Pharma Contract Sales Market

2.1 An Introduction to Pharma Contract Sales
2.2 Pharma Sales Models 2014 – Multiple Channels
2.3 Detailing Healthcare Professionals – Is That Still Relevant?
2.4 There Are Benefits to Outsourcing Pharma Sales
2.4.1 What Services Do CSOs Offer?
2.4.2 The Rise in Pharma Contract Sales
2.5 The Need for New Sales Models – Creative Yet Ethical

3. World Pharma Contract Sales Market: Outlook and Forecast 2015-2025

3.1 World Pharma Contract Sales Market 2014
3.1.1 Pharma Contract Sales Market by Sector 2014
3.1.2 Recent Growth in Outsourced Pharma Sales
3.2 World Pharma Contract Sales Market Forecast 2015-2025
3.2.1 Maturing Brands and New Product Launches to Drive Growth to 2025
3.2.2 Increasing Restraints on Healthcare Budgets to Drive Market Access Consultancy
3.2.3 Pharma Contract Sales: Market Restraints 2015-2025
3.3 Leading Therapeutic Areas for Pharma Contract Sales 2015-2025
3.4 Contract Sales for Cardiovascular Drugs 2015-2025
3.4.1 Growth for Cardiovascular Disease Services: Submarket Forecast 2015-2025
3.5 Metabolic Disorders: Pharma Contract Sales 2015-2025
3.5.1 Metabolic Disorder Services: New Obesity and Diabetes Product Launches Drive to Growth 2015-2025
3.6 Contract Sales for Cancer Drugs 2015-2025
3.6.1 Oncology Sales Services: Submarket Forecast 2015-2025
3.7 Chapter Summary: Strong Growth Forecast for the Pharma Contract Sales Market 2015-2025

4. Leading Service Sectors of the Pharma Contract Sales Market 2015-2025

4.1 Detailing Leads the Contract Sales Market 2014
4.1.1 Rising Demand for Inside and Outside Sales Teams
4.2 Personal Promotion: Contract Detailing Submarket 2015-2025
4.2.1 Detailing Services Offered by CSOs
4.2.2 Contract Detailing: Submarket Forecast 2015-2025
4.2.3 CSOs Are Affected by Doctor Access as Much as Internal Reps
4.2.4 Field Sales Flexibility to Drive Submarket Growth 2015-2025
4.3 Contract Non-Personal Promotion Submarket 2015-2025
4.3.1 Contract Non-Personal Promotion: Submarket Forecast 2015-2025
4.3.1.1 Submarket Drivers and Restraints 2015-2025: Multichannel Marketing
4.3.2 Contract Teledetailing Submarket 2015-2025
4.3.2.1 Submarket Forecast 2015-2025: Rapid Growth in Demand for Contact Centres
4.3.2.2 Contract Teledetailing: Submarket Drivers and Restraints 2015-2025
4.3.3 Contract eDetailing Submarket 2015-2025
4.3.3.1 The Contract Edetailing Submarket Will Grow Fastest 2015-2025
4.3.3.2 Contract Edetailing: Submarket Drivers and Restraints 2015-2025
4.4 Medical Education Services Submarket 2015-2025
4.4.1 Medical Education Services Submarket: Revenue Forecast 2015-2025
4.4.2 Complex Drug Development to Drive Submarket Growth to 2025
4.5 Sample Management Services Submarket 2015-2025
4.5.1 Steady Growth for Sample Management Services to 2025
4.5.2 Sample Management Services: Submarket Drivers and Restraints 2015-2025
4.5.3 J. Knipper & Co.: A US Leader in Sample Management Services
4.5.3.1 J. Knipper Acquires Sample Management Divisions from Leading CSOs 2010-2014
4.5.3.2 New Technologies to Drive Growth 2015-2025
4.6 Chapter Summary: Continued High Demand for Contract Detailing Services

5. Leading National Submarkets for Pharma Contract Sales: Regulatory and Commercial Outlook 2015-2025

5.1 Leading National Submarkets for Pharma Contract Sales 2014
5.2 Leading National Pharma Contract Sales Submarkets: Outlook and Forecast 2015-2025
5.2.1 How Will Market Shares for Leading Countries Change to 2025?
5.3 Pharma Sales Regulatory Developments
5.3.1 Physician Payment Legislation in the US, Europe and Japan 2011-2014
5.3.1.1 The Physician Payment Sunshine Act (PPSA)
5.3.1.2 Physician Payments in France: Increased Scrutiny from 2013
5.3.2 Domestic and International Concerns over Bribery: Recent Legislation in the US and UK
5.3.2.1 Promotional Products in the EU: New Rules 2013
5.3.3 New Market Access Requirements in EU5 Countries 2011-2014
5.3.3.1 AMNOG: Stricter Pricing for Drugs in Germany
5.3.3.2 Healthcare Reform in France: Pricing and Reimbursement Set for Change?
5.3.3.3 Pricing Models and Clinical Commissioning Groups in the UK
5.3.4 Overtime for Sales Reps in the US: Rule Clarifications 2012-2014
5.4 The US Pharma Contract Sales Submarket 2015-2025
5.4.1 Pharma Sales Regulation in the US
5.4.2 US Submarket: Revenue Forecast 2015-2025
5.5 Pharma Contract Sales in the EU 2015-2025
5.5.1 Regulating Pharma Sales in the EU
5.5.2 Commercial Outlook for Pharma Contract Sales in the EU: Submarket Forecast 2015-2025
5.5.3 UK Submarket: Revenue Forecast 2015-2025
5.5.4 Strong Growth for the German Submarket to 2025
5.5.5 French Pharma Contract Sales Submarket: Revenue Forecast 2015-2025
5.5.6 Italian Submarket Forecast 2015-2025: Price Restrictions to Restrain Growth
5.5.7 Spanish Pharma Contract Sales Submarket: Revenue Forecast 2015-2025
5.6 Japanese Pharma Contract Sales: Regulatory and Commercial Outlook 2015-2025
5.6.1 Pharma Contract Sales in Japan 2013-2014
5.6.2 Rise in Outsourcing Rate to Drive Japanese Submarket Growth 2015-2025
5.7 Chapter Summary: Strong Growth for Leading National Submarkets 2015-2025

6. Emerging National Submarkets for Pharma Contract Sales: Regulatory and Commercial Outlook 2015-2025

6.1 Pharma Contract Sales in Emerging National Submarkets 2014
6.2 Outlook for Emerging National Submarkets: Revenue Forecasts 2015-2025
6.3 Improving Regulation for Pharma Sales in Emerging Markets
6.4 Pharma Contract Sales in China 2015-2025
6.4.1 Rising In-House and Outsourced Sales Rep Numbers 2011-2013
6.4.2 Concerns over Bribery in Chinese Pharma Sales
6.4.3 Chinese Pharma Contract Sales Submarket: Revenue Forecast 2015-2025
6.5 India: Pharma Contract Sales Submarket 2015-2025
6.5.1 New Pharma Sales Rules Proposed for 2015
6.5.2 Demand for Field Sales Teams to Drive Growth in the Indian Submarket Growth to 2025
6.6 Pharma Contract Sales in Brazil 2015-2025
6.6.1 State Payment Rules for Drugs in Brazil
6.6.2 Updated Online Marketing Rules for Prescription Drugs
6.6.3 Brazilian Pharma Contract Sales Submarket: Revenue Forecast 2015-2025
6.7 Pharma Contract Sales in Russia 2015-2025
6.7.1 New State Procurement Rules for Drugs 2013
6.7.2 Restricted Interactions between Doctors and Sales Reps in Russia
6.7.3 Russian Pharma Contract Sales Submarket: Revenue Forecast 2015-2025
6.8 Chapter Summary: Outlook for Pharma Contract Sales in Emerging National Markets 2015-2025

7. Pharma Contract Sales: Industry and Market Trends 2015-2025

7.1 Pharma Contract Sales Market: Strengths and Weaknesses 2015
7.2 Pharma Contract Sales Market: Opportunities and Threats 2015-2025
7.3 Pharma Contract Sales Market: STEP Analysis 2015-2025
7.3.1 Social Factors Affecting Pharma Sales to 2025
7.3.1.1 The Role of Ethics in Pharma Sales
7.3.2 Technological Developments to Improve Sales Strategies
7.3.2.1 Smartphones and Tablets for New Detailing Strategies
7.3.2.2 Closed Loop Marketing (CLM)
7.3.2.3 Cloud Computing and its Use Pharma Contract Sales
7.3.2.4 Customer Relationship Management (CRM)
7.3.2.5 Can Big Data Play a Role in Pharma Sales?
7.3.2.6 How Will Pharma Use Social Media in Sales?
7.3.3 Economic Pressures Are Limiting Healthcare and Marketing Budgets
7.3.4 Political Issues: Stricter Regulations for Pharma Sales in Markets Worldwide
7.4 Trends in Outsourced Pharma Sales 2015-2025
7.4.1 Cuts to In-House Sales Staff Will Continue from 2015
7.4.2 Strategic Partnering to Provide Long-Term Revenue Growth
7.4.3 Leading CSOs Will Consolidate to Increase Market Penetration
7.4.4 There Are Risks in Outsourcing Pharma Sales
7.5 Drug Development Trends Affecting Pharma Sales 2015-2025
7.5.1 How Will Orphan Drug Development Influence Pharma Sales?
7.5.2 Promotion for Biosimilars Drugs 2015-2025
7.5.3 There Will be Greater Demand for Specialty Medicine
7.5.4 The Appeal of Emerging National Markets
7.6 New Sales Models Are Needed
7.6.1 Sales Reps Are Struggling for Access to Healthcare Professionals
7.6.2 Multichannel Marketing to Overcome Problems of Access
7.6.3 Key Account Management (KAM)
7.6.4 Silos in Sales and Marketing
7.6.5 The Use of Key Opinion Leaders (KOLs) in Pharma Sales
7.7 Market Access and Contract Medicine Sales
7.7.1 There Are Emerging Stakeholders in Pharma Sales
7.7.2 Changes in Market Access in the US 2015-2025: The Rise of ACOs
7.7.3 Market Access in the EU 2015-2025
7.7.4 The Role of CSOs in Improved Market Access
7.8 Chapter Summary: Main Trends Shaping Pharma Contract Sales 2015-2025

8. Leading Contract Sales Organisations (CSOs), 2015

8.1 Few CSOs Compete on a Global Scale
8.2 Quintiles: World Market Leader for Contract Sales and Market Access
8.2.1 New Services and Strategic Partnerships
8.2.2 Quintiles Integrated Healthcare Services: Performance 2010-2014
8.2.3 Outlook for Quintiles’ Contract Sales 2015-2025
8.3 inVentiv Health
8.3.1 inVentiv is Expanding in Asia
8.3.2 inVentiv’s Commercial Services: Recent Financial Performance
8.3.3 inVentiv Health: Contract Sales Outlook 2015-2025
8.4 UDG Healthcare
8.4.1 Geographic and Service Growth through Acquisitions
8.4.2 UDG Healthcare: Financial Performance 2010-2014
8.4.3 A Leader in Europe 2015-2025?
8.5 North America: Leading Regional-Level CSOs
8.5.1 PDI
8.5.1.1 Broad Service Portfolio
8.5.1.2 New Sales Models for Medical Devices
8.5.1.3 Financial Performance 2010-2014
8.5.1.4 PDI: Contract Sales Outlook 2015-2025
8.5.2 Publicis Touchpoint Solutions
8.5.2.1 New Services in Recent Years
8.5.3 OnCall
8.5.3.1 OnCall Partners with Promius Pharma
8.6 Leading Domestic CSOs in Europe
8.6.1 Marvecs: A Local Leader in Germany
8.6.1.1 New Services Added: Sales 3.0
8.6.2 Sofip: Contract Sales for the French Submarket
8.7 CSOs in the Asia Pacific Region
8.7.1 Global Leaders Dominate in Japan
8.7.2 CMIC Accounts for 10% of Outsourced Sales Reps in Japan
8.7.2.1 CMIC CSO: Financial Performance 2010-2014
8.7.3 Leading Players in China Are Not Just CSOs
8.8 Chapter Summary: Growth Strategies for Market Leaders

9. Interviews from Visiongain's Industry Survey

9.1 Walter R. Dewees, Executive Vice-President, OnCall LLC
9.1.1 OnCall, LLC
9.1.2 Promotional Outsourcing in the US
9.1.3 Increasing Engagement via Technology-Enabled Multi-Channels
9.1.4 Growing Medical Science Liaison Function
9.1.5 Risk-Sharing Agreement
9.2 Tony Swift, Managing Director, Apodi, UK
9.2.1 Apodi
9.2.2 Market Access Challenges in the UK
9.2.3 CSOs Can Promote Partnership Between Pharma and the NHS
9.2.4 Value Propositions Offered by CSOs
9.3 Holger C.W. Fürstenberg, CEO, Hilver, the Netherlands
9.3.1 Hilver
9.3.2 Integrating CLM and Digital Strategy Remains a Challenge
9.3.3 CLM Implementation - Bridging Sales and Marketing
9.3.4 Company Culture is yet to Fully Embrace Digital Toolsets
9.3.5 Digital Tools Facilitate Unparalleled Customer Service

10. Conclusions of the Research and Analysis

10.1 The World Pharma Contract Sales Market in 2014
10.1.1 Contract Detailing Services Dominate CSO Revenues in 2014
10.1.2 Spending on Contract Sales is Highest in the US and EU
10.2 Outlook for the Pharma Contract Sales Market 2015-2025
10.2.1 Growth Trends for Leading Submarkets 2015-2025
10.2.1.1 Therapeutic Sector Growth 2015-2025
10.2.2 Commercial Drivers for Pharma Contract Sales from 2015

List of Tables

Table 1.1 Sales as a Cost for Big Pharma Companies, 2014
Table 1.2 Pharma Contract Sales Industry and Market: Overall Market and Revenue Forecasts by Sector ($bn), 2015-2025
Table 2.1 Benefits and Weaknesses to Outsourcing Pharma Sales, 2015
Table 2.2 Some Big Pharma Sales Force Cuts, Based on Reports and Predictions
Table 3.1 Leading CSO Revenues and CAGRs (%), 2010 and 2014
Table 3.2 Pharma Contract Sales Market: Revenues ($bn), 2010-2014
Table 3.3 Pharma Contract Sales Market: Overall Market and Revenue Forecasts ($bn) by Promotional Activity, 2015-2025
Table 3.4 Pharma Contract Sales Market: Revenues ($bn) and Market Shares (%) by Therapeutic Sector, 2014
Table 3.5 Pharma Contract Sales Market: Therapeutic Submarket Shares (%), 2014-2025
Table 3.6 Cardiovascular Disease Drugs – Patents Expired in 2014
Table 3.7 Cardiovascular Disease Drugs Going Off-Patent, 2015-2025
Table 3.8 Cardiovascular Disease Submarket: Revenue Forecast ($bn), 2014-2025
Table 3.9 Cardiovascular Disease Drugs Approved, 2014-2015
Table 3.10 Metabolic Disorders Drug Off Patent 2016-2022
Table 3.11 Metabolic Disorders Drugs Approved in 2014-2015
Table 3.12 Metabolic Disorder Submarket: Revenue Forecast ($bn), 2014-2025
Table 3.13 Anti-Cancer Drugs Off-Patent, 2015-2020
Table 3.14 Selected Cancer Drugs Facing Market Access Challenges from NICE, 2013-2015
Table 3.15 Oncology Submarket: Revenue Forecast ($bn), 2014-2025
Table 3.16 Anti-Cancer Drugs Approved in 2014-2015
Table 4.1 Pharma Contract Sales Market: Revenues ($bn) and Market Shares (%) by Service Sector, 2014
Table 4.2 Contract Detailing Submarket: Revenues ($bn), 2010-2014
Table 4.3 Contract Detailing Submarket: Revenue Forecast ($bn), 2014-2025
Table 4.4 Contract Non-Personal Promotion Submarket: Revenues ($bn) and Submarket Shares (%) by Sector, 2014
Table 4.5 Contract Non-Personal Promotion: Overall Submarket and Revenue Forecasts ($bn) by Sector, 2014-2025
Table 4.6 Contract Non-Personal Promotion Submarket: Subsector Shares (%), 2014-2025
Table 4.7 Contract Teledetailing Submarket: Revenue Forecast ($bn), 2014-2025
Table 4.8 Contract Edetailing Submarket: Revenue Forecast ($bn), 2014-2025
Table 4.9 Medical Education Services Submarket: Revenue Forecast ($bn), 2014-2025
Table 4.10 Sample Management Services Submarket: Revenue Forecast ($bn), 2014-2025
Table 4.11 Pharma Contract Sales Market: Overall Market and Revenue Forecasts ($bn) by Service Type, 2014-2025
Table 4.12 Pharma Contract Sales: Market Shares (%) by Service Type, 2014-2025
Table 5.1 Pharma Contract Sales Market: Revenues ($bn) and Market Shares (%) by Leading Country, 2014
Table 5.2 Pharma Contract Sales Market: Overall Market and Revenue Forecasts ($bn) by Region, 2014-2025
Table 5.3 Pharma Contract Sales: Market Shares (%) by Region, 2014-2025
Table 5.4 US Pharma Contract Sales Submarket: Revenues ($bn), 1995 and 2014
Table 5.5 US Pharma Contract Sales Submarket: Revenue Forecast ($bn), 2014-2025
Table 5.6 US Pharma Contract Sales Submarket: Drivers and Restraints, 2015-2025
Table 5.7 EU Pharma Contract Sales Submarket: Revenues ($bn) and Submarket Shares (%) by Leading Country, 2014
Table 5.8 EU Pharma Contract Sales Submarket: Overall Submarket and Revenue Forecasts ($bn) by Leading Country, 2014-2025
Table 5.9 EU Pharma Contract Sales Submarket: Drivers and Restraints, 2015-2025
Table 5.10 UK Pharma Contract Sales Submarket: Revenue Forecast ($bn), 2014-2025
Table 5.11 German Pharma Contract Sales Submarket: Revenue Forecast ($bn), 2014-2025
Table 5.12 French Pharma Contract Sales Submarket: Revenue Forecast ($bn), 2014-2025
Table 5.13 Italian Pharma Contract Sales Submarket: Revenue Forecast ($bn), 2014-2025
Table 5.14 Spanish Pharma Contract Sales Submarket: Revenue Forecast ($bn), 2014-2025
Table 5.15 Japanese Pharma Contract Sales Submarket: Revenue Forecast ($bn), 2014-2025
Table 5.16 Japanese Pharma Contract Sales Submarket: Drivers and Restraints, 2015-2025
Table 6.1 Pharma Contract Sales Market: Revenue Forecasts ($bn) for Four Leading Emerging Countries (BRIC Nations), 2014-2025
Table 6.2 Pharma Contract Sales: Leading Emerging Market Shares (%), 2014-2025
Table 6.3 Chinese Pharma Contract Sales Submarket: Drivers and Restraints, 2015-2025
Table 6.4 Chinese Pharma Contract Sales Submarket: Revenue Forecast ($bn), 2014-2025
Table 6.5 Indian Pharma Contract Sales Submarket: Revenue Forecast ($bn), 2014-2025
Table 6.6 Indian Pharma Contract Sales Submarket: Drivers and Restraints, 2015-2025
Table 6.7 Brazilian Pharma Contract Sales Submarket: Drivers and Restraints, 2015-2025
Table 6.8 Brazilian Pharma Contract Sales Submarket: Revenue Forecast ($bn), 2014-2025
Table 6.9 Russian Pharma Contract Sales Submarket: Drivers and Restraints, 2015-2025
Table 6.10 Russian Pharma Contract Sales Submarket: Revenue Forecast ($bn), 2014-2025
Table 7.1 Pharma Contract Sales Market: Strengths and Weaknesses, 2015
Table 7.2 Pharma Contract Sales Market: Opportunities and Threats, 2015-2025
Table 7.3 Selected Blockbuster US Patent Expiries from 2014
Table 7.4 Pharma Contract Sales Market: STEP Analysis, 2015-2025
Table 7.5 Selected CRM Service Providers for Pharma Sales, 2015
Table 7.6 Orphan Drug Definitions in Leading Countries, 2013
Table 7.7 Orphan Drug Pipeline by Disease Area, 2013
Table 8.1 Leading CSOs: Contract Sales and Commercial Service Revenues ($bn), 2013-2014
Table 8.2 Quintiles: Emerging Market Entries: 2010-2012
Table 8.3 Quintiles: Integrated Healthcare Services Revenue ($bn), 2010-2014
Table 8.4 inVentiv Health: Commercial Division Subsidiaries, 2015
Table 8.5 inVentiv Health: Commercial Revenue ($bn), 2010-2014
Table 8.6 UDG Healthcare: Contract Sales Subsidiaries, 2013
Table 8.7 UDG Healthcare: Sales, Marketing and Medical Revenue ($bn), 2010-2014
Table 8.8 PDI: Commercial Services Revenue ($bn), 2010-2014
Table 8.9 Sofip: Revenue ($bn), 2010-2014
Table 8.10 CMIC: CSO Revenue ($bn), 2010-2014
Table 10.1 Pharma Outsourcing Market: Revenues ($bn) and Market Shares (%) by Sector, 2014
Table 10.2 Pharma Contract Sales Market: Revenue Forecasts ($bn) and Market Shares (%) by Service Type 2014, 2019, 2025
Table 10.3 Pharma Contract Sales Market: Revenue Forecasts ($bn) and Market Shares (%) by Therapeutic Area, 2014, 2019 and 2025

List of Figures

Figure 2.1 Services Offered by CSOs in the Pharma Contract Sales Market, 2015
Figure 2.2 Outsourcing Processes in the Pharmaceutical Industry, 2015
Figure 2.3 Trends Driving the Need for New Sales Models, 2015-2025
Figure 3.1 Pharma Contract Sales Market: Revenues ($bn), 2010-2014
Figure 3.2 Pharma Contract Sales Market: Revenue Forecast ($bn), 2015-2025
Figure 3.3 Pharma Contract Sales: Market Drivers, 2015-2025
Figure 3.4 FDA: New Drug Approvals, Numbers, 2010-2014
Figure 3.5 Pharma Contract Sales: Market Restraints, 2015-2025
Figure 3.6 Pharma Contract Sales: Market Shares (%) by Therapeutic Sector, 2014
Figure 3.7 Pharma Contract Sales: Market Shares (%) by Therapeutic Sector, 2019
Figure 3.8 Pharma Contract Sales: Market Shares (%) by Therapeutic Sector, 2025
Figure 3.9 Cardiovascular Disease Submarket: Revenue Forecast ($bn), 2014-2025
Figure 3.10 Metabolic Disorder Submarket: Revenue Forecast ($bn), 2014-2025
Figure 3.11 Oncology Submarket: Revenue Forecast ($bn), 2014-2025
Figure 4.1 Pharma Contract Sales: Market Shares (%) by Service Type, 2014
Figure 4.2 Contract Detailing Submarket: Revenues ($bn), 2010-2014
Figure 4.3 Contract Detailing Submarket: Revenue Forecast ($bn), 2014-2025
Figure 4.4 Contract Detailing Submarket: Drivers and Restraints, 2015-2025
Figure 4.5 Contract Non-Personal Promotion: Submarket Shares (%) by Sector, 2014
Figure 4.6 Contract Non-Personal Promotion Submarket: Revenue Forecast ($bn), 2014-2025
Figure 4.7 Contract Non-Personal Promotion: Submarket Shares (%) by Sector, 2019
Figure 4.8 Contract Non-Personal Promotion: Submarket Shares (%) by Sector, 2025
Figure 4.9 Contract Non-Personal Promotion Submarket: Drivers and Restraints, 2015-2025
Figure 4.10 Contract Teledetailing Submarket: Revenue Forecast ($bn), 2014-2025
Figure 4.11 Contract Teledetailing Submarket: Drivers and Restraints, 2015-2025
Figure 4.12 Contract Edetailing Submarket: Revenue Forecast ($bn), 2014-2025
Figure 4.13 Contract Edetailing Submarket: Drivers and Restraints, 2015-2025
Figure 4.14 Medical Education Services Submarket: Revenue Forecast ($bn), 2014-2025
Figure 4.15 Medical Education Services Submarket: Drivers and Restraints, 2015-2025
Figure 4.16 Sample Management Services Submarket: Revenue Forecast ($bn), 2014-2025
Figure 4.17 Sample Management Services Submarket: Drivers and Restraints, 2015-2025
Figure 4.18 Pharma Contract Sales: Market Shares (%) by Service Type, 2019
Figure 4.19 Pharma Contract Sales: Market Shares (%) by Service Type, 2025
Figure 5.1 Pharma Contract Sales: Market Shares (%) by Region, 2014
Figure 5.2 Pharma Contract Sales: Market Shares (%) by Region, 2019
Figure 5.3 Pharma Contract Sales: Market Shares (%) by Region, 2025
Figure 5.4 US Pharma Contract Sales Submarket: Revenues ($bn), 1995 and 2014
Figure 5.5 US Pharma Contract Sales Submarket: Revenue Forecast ($bn), 2014-2025
Figure 5.6 EU Pharma Contract Sales: Leading National Submarket Shares (%), 2014
Figure 5.7 EU Pharma Contract Sales Submarket: Revenue Forecast ($bn), 2014-2025
Figure 5.8 UK Pharma Contract Sales Submarket: Revenue Forecast ($bn), 2014-2025
Figure 5.9 Growing Rate of Outsourced Sales Reps in Germany, 2003-2013
Figure 5.10 German Pharma Contract Sales Submarket: Revenue Forecast ($bn), 2014-2025
Figure 5.11 French Pharma Contract Sales Submarket: Revenue Forecast ($bn), 2014-2025
Figure 5.12 Italian Pharma Contract Sales Submarket: Revenue Forecast ($bn), 2014-2025
Figure 5.13 Spanish Pharma Contract Sales Submarket: Revenue Forecast ($bn), 2014-2025
Figure 5.14 Japanese Pharma Contract Sales Submarket: Revenue Forecast ($bn), 2014-2025
Figure 6.1 Pharma Contract Sales: Emerging National Market Shares (%), 2019
Figure 6.2 Pharma Contract Sales: Emerging National Market Shares (%), 2025
Figure 6.3 Chinese Pharma Contract Sales Submarket: Revenue Forecast ($bn), 2014-2025
Figure 6.4 Indian Pharma Contract Sales Submarket: Revenue Forecast ($bn), 2014-2025
Figure 6.5 Brazilian Pharma Contract Sales Submarket: Revenue Forecast ($bn), 2014-2025
Figure 6.6 Russian Pharma Contract Sales Submarket: Revenue Forecast ($bn), 2014-2025
Figure 7.1 Orphan Drug Pipeline by Disease Area, 2013
Figure 8.1 Leading CSOs: Contract Sales and Commercial Service Revenues ($bn), 2013-2014
Figure 8.2 Quintiles: Integrated Healthcare Services Revenue ($bn), 2010-2014
Figure 8.3 inVentiv Health: Commercial Revenue ($bn), 2010-2014
Figure 8.4 UDG Healthcare: Sales, Marketing and Medical Revenue ($bn), 2010-2014
Figure 8.5 PDI: Revenue ($bn), 2010-2014
Figure 8.6 Sofip: Revenue ($bn), 2010-2014
Figure 8.7 CMIC: CSO Revenue ($bn), 2010-2014
Figure 10.1 Pharma Outsourcing: Market Shares (%) by Sector, 2014
Figure 10.2 Pharma Contract Sales Market: Revenue Forecasts ($bn) by Service Type, 2014, 2019 and 2025
Figure 10.3 Pharma Contract Sales Market: Revenue Forecast ($bn) by Therapeutic Area, 2014, 2019 and 2025

掲載企業リスト

Companies Listed

AbbVie
Actavis
Actelion
Agência Nacional de Vigilância Sanitária (ANVISA)
Allergan
Amgen
Apodi
Apple
Arbor Pharms Ireland
Arena Pharmaceuticals
Arista
Ashfield Healthcare
AstraZeneca
Bayer Healthcare
Biogaran
Boehringer Ingelheim
Bristol-Myers Squibb
Catalina Health
Cegedim
Chinese Ministry of Health
Clinical Commissioning Groups (CCGs)
CMIC
Daiichi Sankyo
Dayarn Pharma
Dendreon
Depomed
Eisai
Eli Lilly
Endo Pharmaceuticals
European Federation of Pharmaceutical Industries and Associations (EFPIA)
Expansis
Financial Services Authority (FSA)
Food and Drug Administration (US FDA)
German Federal Court
Gilead
GlaxoSmithKline (GSK)
Go!
Grey Healthcare Group
Health Kare Pharma International
Healthcare Marketing
Helsinn
Hilver
Hospira
In2Focus
Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesenis (IQWiG)
International Federation of Pharmaceutical Manufacturers & Associations (IFPMA)
inVentive Health
Invida
J. Knipper & Co.
Japan Contract Sales Organization Association (JCSOA)
Johnson&Johnson
Kadrige
L’Agenzia Italiana del Farmaco (AIFA)
Lupin
Mannkind
Marvecs
Medical Communications Group (MCG)
Medical Council of India (MCI)
MediMedia Health
Menarini Asia-Pacific
Merck & Co.
Merqurio Pharma
Microsoft
Ministère des Affaires Sociales et de la Santé
MKM
National Health Service (UK NHS)
National Institute for Health and Care Excellence (UK NICE)
Neurocrine Biosciences
Norwegian Medicines Agency
NovaMed Pharmaceuticals
Novartis
Novo Nordisk
OnCall LLC
Oracle
Otsuka
PDI Healthcare
Pfizer
Pharmaceutical Producers of India (OPPI)
Pharmaceutical Research and Manufacturers of America (PhRMA)
Pharmacyclics
Pharmagistics
Pharmexx
Polpharma
Promius Pharma
Publicis Healthcare Communications Group
Publicis Touchpoint Solutions
Qforma
Quintiles
Ramco Import Export
Roche
Rossetti Marketing
Salesforce
Sanofi
Schering-Plough
Scientific Voice
Sermo
Servier
Sinclair IS Pharma
Smithkline Beecham
Sofip
Solvay
Spectrum Pharmaceuticals
StayInFront
Symplmed Pharmaceuticals
Synopia Rx
Takeda
Temas
Temasek Holdings
Teva Pharmaceutical Industries
Thomas H. Lee Partners
Transgenomic
UDG Healthcare
US Congressional Budget Office
Veeva
Vivus
Warner Chilcott
Zuellig Pharma

プレスリリース

プレスリリース

Memo.png当レポートのプレスリリースは発行されておりません。

2319881.jpg国内外のスマートグリッド関連ニュース、リサーチ情報等を収集し隔週でお届けいたします。日本そして海外の企業動向、新製品、政府支援、技術開発、規格、導入事例、投資、調査発表など幅広く情報を定期配信いたします。
スマートグリッド・ニュースへLinkIcon


ニュースページへLinkIcon

資料検索

お探しの資料・レポートをキーワードで検索ください。

当サイト内の検索結果が表示されます。調査レポートは英文目次を掲載しているため、英語検索も有効です。
(ブラウザのスクリプトを有効にしないとサーチエンジンが表示されません)

お問い合わせ

2714110_0.jpg
レポートをお探しいたします。
当サイトに掲載されているレポート以外にも幅広くご提案可能です。レポートの内容に関するご質問、ご確認にも回答いたします。お気軽にお問い合わせください。